Hirsutism secondary prevention

Jump to navigation Jump to search

Hirsutism Microchapters


Patient Information


Historical Perspective




Differentiating Hirsutism from other Diseases

Epidemiology and Demographics

Risk Factors


Natural History, Complications and Prognosis


Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings



Echocardiography or Ultrasonography


Medical Therapy

Pharmacological therapy
Non-pharmacological therapy


Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hirsutism secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides


Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hirsutism secondary prevention

CDC on Hirsutism secondary prevention

Hirsutism secondary prevention in the news

Blogs on Hirsutism secondary prevention

Directions to Hospitals Treating Hirsutism secondary prevention

Risk calculators and risk factors for Hirsutism secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rasam Hajiannasab M.D.[2] Eiman Ghaffarpasand, M.D. [3]


Effective measures for the secondary prevention of hirsutism include lifestyle modification and pharmacological prevention. The goal of secondary prevention is to prevent cardiovascular and metabolic diseases (diabetes mellitus).

Secondary Prevention

  • Effective measures for the secondary prevention of hirsutism include lifestyle modification and pharmacological prevention.

Lifestyle modification

Pharmacological prevention


  1. Karimzadeh MA, Javedani M (2010). "An assessment of lifestyle modification versus medical treatment with clomiphene citrate, metformin, and clomiphene citrate-metformin in patients with polycystic ovary syndrome". Fertil. Steril. 94 (1): 216–20. doi:10.1016/j.fertnstert.2009.02.078. PMID 19463994.
  2. Graff SK, Mário FM, Alves BC, Spritzer PM (2013). "Dietary glycemic index is associated with less favorable anthropometric and metabolic profiles in polycystic ovary syndrome women with different phenotypes". Fertil. Steril. 100 (4): 1081–8. doi:10.1016/j.fertnstert.2013.06.005. PMID 23830153.
  3. Nieuwenhuis-Ruifrok AE, Kuchenbecker WK, Hoek A, Middleton P, Norman RJ (2009). "Insulin sensitizing drugs for weight loss in women of reproductive age who are overweight or obese: systematic review and meta-analysis". Hum. Reprod. Update. 15 (1): 57–68. doi:10.1093/humupd/dmn043. PMID 18927072.
  4. Franks, Stephen (2012). "The investigation and management of hirsutism". Journal of Family Planning and Reproductive Health Care. 38 (3): 182–186. doi:10.1136/jfprhc-2011-100175. ISSN 1471-1893.

Template:WH Template:WS